Theodossi A, Eddleston A L, Williams R
Gut. 1982 Jan;23(1):75-9. doi: 10.1136/gut.23.1.75.
The efficacy of methylprednisolone (1 g daily or three days), which is effective in reversing transplant rejection, was assessed in a randomised controlled trial of 55 patients with severe acute alcoholic hepatitis, 34 of whom had encephalopathy. The clinical progress, frequency of bleeding and sepsis, and cause of death were similar in the treatment (27 patients) and control groups (28 patients). There was no significant difference in mortality rate between the two groups: 57% of the control group and 63% of the treatment group died during the study. Patients' survival depended on the presence of absence of the following features: encephalopathy, serum bilirubin concentration more than 340 micromol/l, serum creatinine concentration more than 250 micromol/l, and histological evidence of cirrhosis as well as severe acute alcoholic hepatitis.
在一项针对55例重症急性酒精性肝炎患者的随机对照试验中，评估了甲泼尼龙（每日1克或连用三天）逆转移植排斥反应的疗效，其中34例患者伴有肝性脑病。治疗组（27例患者）和对照组（28例患者）的临床进展、出血和败血症发生率以及死亡原因相似。两组的死亡率无显著差异：在研究期间，对照组57%的患者和治疗组63%的患者死亡。患者的生存取决于是否存在以下特征：肝性脑病、血清胆红素浓度超过340微摩尔/升、血清肌酐浓度超过250微摩尔/升、肝硬化的组织学证据以及重症急性酒精性肝炎。
